With second FDA approval, the transformative power of CAR-T is multiplied – Penn: Office of University Communications
Penn: Office of University Communications |
With second FDA approval, the transformative power of CAR–T is multiplied
Penn: Office of University Communications The technology behind Kymriah originated at Penn from the innovative work led by Penn Medicine's Carl June in developing the CAR-T platform for reprogramming T cells. An initial cohort of patients was treated with the CAR–T cell therapy at Penn, with … |
